Abstract
BACKGROUND—Ipratropium is commonly used for the management of elderly patients with obstructive airway disease. However, a recent report suggested that its use might be associated with a significant increase in mortality. A study was therefore conducted to compare all-cause mortality rates between users and non-users of ipratropium in elderly patients with either asthma or chronic obstructive pulmonary disease (COPD). METHODS—A retrospective cohort study was performed using linked data from the Canadian Institute for Health Information, the Ontario Drug Benefit Program, the Ontario Health Insurance Plan, and the Ontario Registered Persons database. A total of 32 393 patients were identified who were aged 65 years or older and who had been discharged from hospital with asthma or COPD between 1 April 1992and 31 March 1997. All-cause mortality rates were compared between those treated and those not treated with ipratropium following discharge from hospital. RESULTS—In total, 49% of patients received ipratropium within 90 days of discharge. After adjusting for age, sex, comorbidity, use of health services, and other airway medications there was no significant association in patients with COPD between the use of ipratropium and mortality (relative risk (RR) 1.03; 95% confidence interval (CI) 0.98 to 1.08). In patients with asthma, however, there was a slight increase in the relative risk of mortality associated with the use of ipratropium (RR 1.24; 95% CI 1.11 to 1.39). A dose-response increase in the mortality rate was not observed with increasing use of ipratropium in either COPD or asthma. CONCLUSIONS—The use of ipratropium in patients with COPD was not associated with an increase in mortality. However, in asthma there was a small increase in the mortality rate. Since asthmatic patients who received ipratropium had greater use of other airway medications and health services, the difference in mortality rate between users and non-users may be a reflection of unmeasured differences in asthma severity.
Full Text
The Full Text of this article is available as a PDF (108.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Deyo R. A., Cherkin D. C., Ciol M. A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–619. doi: 10.1016/0895-4356(92)90133-8. [DOI] [PubMed] [Google Scholar]
- Feinleib M., Rosenberg H. M., Collins J. G., Delozier J. E., Pokras R., Chevarley F. M. Trends in COPD morbidity and mortality in the United States. Am Rev Respir Dis. 1989 Sep;140(3 Pt 2):S9–18. doi: 10.1164/ajrccm/140.3_Pt_2.S9. [DOI] [PubMed] [Google Scholar]
- Gross N. J. Ipratropium bromide. N Engl J Med. 1988 Aug 25;319(8):486–494. doi: 10.1056/NEJM198808253190806. [DOI] [PubMed] [Google Scholar]
- Guite H. F., Dundas R., Burney P. G. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax. 1999 Apr;54(4):301–307. doi: 10.1136/thx.54.4.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rawson N. S., Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med. 1995 Dec 30;14(24):2627–2643. doi: 10.1002/sim.4780142404. [DOI] [PubMed] [Google Scholar]
- Rennard S. I., Serby C. W., Ghafouri M., Johnson P. A., Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996 Jul;110(1):62–70. doi: 10.1378/chest.110.1.62. [DOI] [PubMed] [Google Scholar]
- Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
- Suissa S., Ernst P., Boivin J. F., Horwitz R. I., Habbick B., Cockroft D., Blais L., McNutt M., Buist A. S., Spitzer W. O. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604–610. doi: 10.1164/ajrccm.149.3.8118625. [DOI] [PubMed] [Google Scholar]